🇺🇸 FDA

Intelligence Platform

Patents

Browse 750 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12275964

Variant type V CRISPR/Cas effector polypeptides and methods of use thereof

The Regents of the University of California · Granted Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269803

Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease

United States Government as represented by the Department of Veterans Affairs · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12257288

Methods of inducing immune tolerance to clotting factors

BIOVERATIV THERAPEUTICS INC. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246057

Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12247226

Cellular reprogramming using temporal and transient plasmid vector expression system

Fate Therapeutics, Inc. · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240914

Antibody against factor XIa in activated form of coagulant factor XI, preparation method t

MAB-LEGEND BIOTECH CO., LTD. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240918

Bispecific antibodies against plasma kallikrein and factor XII

Takeda Pharmaceutical Company Limited · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12239692

Adeno-associated virus factor VIII vectors

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226437

Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord

China Medical University · Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12214023

Compositions and methods for expressing factor IX

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12213996

Methods of treating optic nerve diseases using neural progenitor cell growth factors

REGENERATIVE RESEARCH FOUNDATION · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12213998

Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal

Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12214031

Mannheimia haemolytica vector

The United States of America, as represented by the Secretary of Agriculture · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201721

Clotting factor preparations for delivery into tissue of the intestinal tract using a swal

Rani Therapeutics, LLC · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188039

Recombinant adeno-associated viral vector for gene delivery

The Board of Regents of the University of Texas System · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186375

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

BIOVERATIV THERAPEUTICS INC. · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173274

Enhanced immune effector cells and use thereof

Fate Therapeutics, Inc. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171741

2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors

NIKANG THERAPEUTICS, INC. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173317

Use of histone modifiers to reprogram effector T cells

The Board of Regents of the University of Texas System · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173307

Methods for the purification of viral vectors

BIOVERATIV THERAPEUTICS INC. · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161696

Methods of treating hemophilic arthropathy using chimeric clotting factors

BIOVERATIV THERAPEUTICS INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161724

Compositions and methods related to tumor activated antibodies targeting EGFR and effector

JANUX THERAPEUTICS, INC. · Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156877

Methods of treating conditions related to a thiamine deficiency, a thiamine-dependent enzy

The Regents of the University of California · Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139528

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted